Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar;313(12):1213-4.
doi: 10.1001/jama.2015.1617.

Naltrexone extended-release plus bupropion extended-release for treatment of obesity

Susan Z Yanovski  1 , Jack A Yanovski  2
Affiliations

Naltrexone extended-release plus bupropion extended-release for treatment of obesity

Susan Z Yanovski et al. JAMA. 2015 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

SZY reports no conflicts of interest. JAY reports that in 2015 he will be a site Principal Investigator for a multi-center trial to be conducted under a CRADA between NICHD and Zafgen Inc. to study beloranib for amelioration of obesity in the Prader-Willi syndrome.

References

    1. . CONTRAVE Package Insert Revised 9/2014 (naltrexone HCl and bupropion HCl) Extended-Release Tablets. La Jolla, CA 92037: Orexigen Therapeutics, Inc; 2014.
    1. Yanovski SZ, Yanovski JA. Long-term Drug Treatment for Obesity: A Systematic and Clinical Review. JAMA: the journal of the American Medical Association. 2014 Jan 1;311(1):74–86. - PMC - PubMed
    1. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005 Apr 5;142(7):532–546. - PubMed
    1. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010 Aug 21;376(9741):595–605. - PubMed
    1. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II) Obesity. 2013 May;21(5):935–943. - PMC - PubMed

Publication types